B-
BiotechTV - News
STIFEL 2026: With expertise in the next generation of GPCR development, Septerna will have initial in human data on its oral PTH19 agonist for hypoparathyroidism in Q1
0:00-9:14
Co-Founder & CEO Jeff Finer walks us through the company's GPCR discovery platform, and discusses, this lead program, a new target (TSHR) they just named in Grave's disease and thyroid eye disease, and the company's work in obeisty with partner Novo Nordisk.
Publisher
BiotechTV - News
Link
podcasters.spotify.com/pod/show/biotechtv4/episodes/STIFEL-2026-With-expertise-in-the-next-generation-of-GPCR-development--Septerna-will-have-initial-in-human-data-on-its-oral-PTH19-agonist-for-hypoparathyroidism-in-Q1-e3s7our
Published
November 11, 2026
Duration
9 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
BiotechTV
B-
BiotechTV - News
@biotechtvnews
#gpcrdevelopment #humandata #oralpth19agonist #lifesciences
